Safety, feasibility and preliminary efficacy of single agent combretastatin A1 diphosphate (OXi4503) in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic syndromesChristopher R. Cogle, Fatih M. Uckun, Raphael C. Bosse et al.|British Journal of Haematology|2020Cited by 15
A Phase I Study Of The Vascular Disrupting Combretastatin, OXi4503, In Patients With Relapsed and Refractory Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS)Daniel Turner, Christopher R. Cogle, Andrés González et al.|Blood|2013Cited by 12